SION (Sionna Therapeutics) Margin of Safety % (DCF Earnings Based): N/A (As of Jul. 04, 2026)


SION Sionna Therapeutics Inc SION
12 GF Score
Price $43.99
! 3 Warning Signs
View Full Analysis

What is Sionna Therapeutics Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Sionna Therapeutics's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

SION vs TYRA, RAPP, IOVA: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, Sionna Therapeutics's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sionna Therapeutics Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sionna Therapeutics's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Sionna Therapeutics's Margin of Safety % (DCF Earnings Based) falls into.


SION
12GF Score
Sionna Therapeutics Inc SION
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sionna Therapeutics Business Description

Address 21 Hickory Drive, Suite 500, Waltham, MA, USA, 02451
Sionna Therapeutics Inc is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefits to CF patients. CF is a progressive and life-threatening genetic disease caused by inherited mutations in the CFTR gene, which heads to insufficient CFTR function. The Company is managed as one operating segment focused on the research and development of cystic fibrosis therapies.
12GF Score

Get the complete analysis for SION

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$43.99
Price